<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>Anti-cancer drugs</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,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)}
		.xchecked-box {list-style-image: url(data:image/png;base64,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)}
		.unchecked-box {list-style-image: url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABgAAAAYCAYAAADgdz34AAAAAXNSR0IArs4c6QAAAAZiS0dEAP8A/wD/oL2nkwAAAAlwSFlzAAANOgAADMQBiN+4gQAAAAd0SU1FB9gKGQ8qAt8h3m8AAAAZdEVYdENvbW1lbnQAQ3JlYXRlZCB3aXRoIEdJTVBXgQ4XAAAA60lEQVRIx+2VsQqDMBRF70sCLg5OLoKgjk7+lJ/hh+STXBwcnRz8ArMEkrxOFktbaC3tULzTg5e8k5vADXDq70VbobXmvu/hvQczg4heHrJfXxQFuq67blZbMc8zpmlCXddIkgTOuZcBUko45zCOI6y1Nz2xFSEEZFmGOI7fGg4A3nsQEZqmuXOu9jallACAtm3fvmutNaIoAjM/dkBECCF89KCbk4eAb+kEnIAT8EsAM0OIz3hSyrssUvss8t5fg+uIrLXPs0gIgWVZYIyBUurQyYdheO4gz3NUVQVjDNZ1PfSjpWmKsixvehfB9GBZ3NndrgAAAABJRU5ErkJggg==)}
		.migrated-box {list-style-image: url(data:image/png;base64,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)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./Pharmacognosy.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='..\21.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>Anti-cancer drugs <a name='20:Pharmacology'></a></h1>
	</div>

	<div class='content'>
	
<p>
<img src="./Pharmacology/pasted_image.png"><img src="./Pharmacology/pasted_image001.png">
</p>
<h1>I.OVERVIEW</h1>

<p>
→ systemic chemotherapy<br>
<ul style='padding-left: 30pt'>
<li>result in cure  		or </li>
<li>porlonged remission</li>
</ul>
</p>

<h1>II.Pricniples of Cancer Chemotherapy</h1>

<p>
→ chemotherapy cause<br>
<ul style='padding-left: 30pt'>
<li>lethal cytotoxic event</li>
<li>apoptosis in the cancer cell</li>
</ul>
→ attack generally directed<br>
<ul style='padding-left: 30pt'>
<li>DNA</li>
<li>metabolic site essential to cell replication
<ul>
<li>[e.g. // purines/pyrimidines that are building block for DNA/RNA synthesis]</li>
</ul></li>
</ul>
<img src="./Pharmacology/pasted_image002.png"><br>
→ anticancer drugs<br>
<ul style='padding-left: 30pt'>
<li>DO NOT recognize neoplastic cells
<ul>
<li>but affect all kinds of profilating cells [both normal and abnormal]</li>
</ul></li>
</ul>
</p>

<h1>II.Treatment strategies</h1>

<br>

<h1>II.A.1-Goals of treatment</h1>

<p>
→ cure (long-term , disease-free survival)<br>
→ control of the disease<br>
<ul style='padding-left: 30pt'>
<li>stop enlarging or spreading.</li>
<li>extend survival of human</li>
<li>maintain best quality of life as possible</li>
</ul>
→ first cell is burden by <br>
<ul style='padding-left: 30pt'>
<li>surgery and/or radiation followed</li>
<li>by chemotherapy</li>
<li>immunotherapy</li>
<li>or combination of these treatment </li>
</ul>
</p>

<h1>II.A.2-Indication for treatment</h1>

<p>
→ when neoplasm are disseminated<br>
<ul style='padding-left: 30pt'>
<li>and are not amenable to surgery</li>
</ul>
→ as a supplemental treatment to attack micrometastases following<br>
<ul style='padding-left: 30pt'>
<li>surgery and radiation treatment in which called "adjuvant"</li>
</ul>
→ or given prior to surgical procedure<br>
<ul style='padding-left: 30pt'>
<li>lower doses to assist prolonging a remission </li>
</ul>
</p>

<h1>II.A.3.-Tumor susceptibility and the growth-cycle</h1>

<p>
→ rapidly dividing cells<br>
<ul style='padding-left: 30pt'>
<li>more sensitive to anticancer drugs</li>
<li>slowing profilating cells are less sensitive to chemotherapy</li>
</ul>
→ non-profilating cells (G0 phase)<br>
<ul style='padding-left: 30pt'>
<li>usually survive the toxic effects</li>
</ul>
</p>

<h1>II.A.3.a-Cell cycle specificity of drugs</h1>

<p>
→ effective only against replicating<br>
<ul style='padding-left: 30pt'>
<li>cell-cycle specific</li>
</ul>
→ non-specific drugs<br>
<ul style='padding-left: 30pt'>
<li>more toxicity in cycling cellls</li>
<li>low percentage of replicating cells</li>
</ul>
</p>

<h1>II.A.3.b-Tumor growth rate</h1>

<p>
→ growth rate of most solid tumors<br>
<ul style='padding-left: 30pt'>
<li>initialy rapid </li>
</ul>
→ but growth rate ↓<br>
<ul style='padding-left: 30pt'>
<li>as the tumor cell size increases</li>
</ul>
[due to unavailability of nutrients and oxygen which caused by vascularization and lack of blood circulation]<br>
→ ↓ the tumor burden often promotes<br>
<ul style='padding-left: 30pt'>
<li>recruitment fo the remaining cells into active profilation</li>
<li>↑ thei susceptibility to chemotherapeutics agents</li>
</ul>
</p>

<h1>II.B.-Treatment regimens and scheduling</h1>

<p>
→ on the basis of body surface area
</p>

<h1>II.B.1.-Log kill</h1>

<p>
→ first order kinetics<br>
<ul style='padding-left: 30pt'>
<li>given dose of drug destroys a constant fraction of cells</li>
</ul>
[e.g// 10(9) total leukemic cells → treatment leads to 99.999% kill → means that 10(4)of cells would remain
</p>

<h1>II.B.2-Pharmacological sanctuaries</h1>

<p>
→ CNS tissues prevent the chemotherapeutics fron entering<br>
→ irradiation of the craniospinal axis or intrathecal admin. of drugs to eliminate the leukemic cells at the site
</p>

<h1>II.B.3-Treatment protocols</h1>

<p>
→ combination-drug therapy is more t succesful than singe-drug treatment
</p>

<h1>II.B.3.a-Combination of drugs</h1>

<p>
→ cytotoxic agents <br>
<ul style='padding-left: 30pt'>
<li>different toxicities</li>
<li>different molecular sites and mechanism of action</li>
<li>combined at full doses
<ul>
<li>result in higher rate of response.</li>
</ul></li>
</ul>
</p>

<h1>II.B.3.b-Advantages of drug combination</h1>

<p>
<ol type="1" start="1">
<li>provide maximal cell killing within the range of tolerated toxicity</li>
<li>effective against a broader range of cell lines</li>
<li>may delay or prevent the developement of resistant cell lines.</li>
</ol>
</p>

<h1>II.B.c-Treatment protocols</h1>

<p>
→ protocols are applicable to a particular neopolastic state<br>
→ e.g.// POMP<br>
<ul style='padding-left: 30pt'>
<li>Prednisone Onvovin Methotrexate Purinethol</li>
<li>21 days apart</li>
</ul>
</p>

<h1>II.C.-Problems associated with chemotherapy</h1>

<p>
→ toxins that present a lethat threat to the cells<br>
<ul style='padding-left: 30pt'>
<li>also including mechanisms that protect themselfs</li>
</ul>
</p>

<h1>II.C.1.Resistance</h1>

<p>
→some have inherrently resistance to most anti-cancer drugs.<br>
→ muatation [particulary after prolonged admin. of suboptimal drug doses]<br>
→ minimized by short-term,intensive,intermittent therapy with combination of  dugs<br>
→ combination are also effective against a broader range of resistant cells
</p>

<h1>II.C.2-Multidrug resistance</h1>

<p>
→ adenosine-triphosphate-dependent pumping of drugs out of the cell<br>
→ in the presence of P-glycoprotein<br>
→ corss-resistance following the use of unrelated agents also occurs<br>
→ P-glycoprotein found  in higher levels<br>
<ul style='padding-left: 30pt'>
<li>kideny,liver,pacnreas,small intestine,colon,adrenal gland.</li>
</ul>
<ul>
<li>certain drugs at high concentration (verapaiml)
<ul>
<li>can inhibit the pump and thus interfere with the efflux of the anticancer agent.</li>
</ul></li>
</ul>
</p>

<h1>II.C.3.-Toxicity</h1>

<p>
→ killing rapidly dividing cancer cells<br>
<ul style='padding-left: 30pt'>
<li>affects normal cells undergoing rapid profilation 
<ul>
<li>bucca muscosal,bone marrow,GI muscosa,hair folicales.</li>
</ul></li>
</ul>
</p>

<h1>II.C.3.a-Common adverse effects</h1>

<p>
→ narrow therapeutic index<br>
<ul style='padding-left: 30pt'>
<li>severe vomiting [admin. of antiemetic agents]</li>
<li>stomatitis</li>
<li>bone marrow suppression</li>
<li>alopecia [transient]</li>
<li>and others based on specific agents</li>
</ul>
</p>

<h1>II.C.3.b.-Minimizing adverse effects</h1>

<p>
→ may be ameliorated by intervention<br>
→ use cytoprotectant drugs <br>
<ul style='padding-left: 30pt'>
<li>perfusing the tumor locacly </li>
<li>removing some of the patients' marrow prior to intensive treatment</li>
<li>intensive diuresis preventing bladder toxicities.</li>
</ul>
→ megaloplastic anemia<br>
<ul style='padding-left: 30pt'>
<li>by admin. of folinic acid</li>
</ul>
</p>

<h1>III.ANTIMETABOLITES</h1>

<p>
→ structually related to normal compounds within the cell<br>
<ul style='padding-left: 30pt'>
<li>interfere with the availability of normal purines/pyrimidine nucleotide prescursors
<ul>
<li>either by inhibiting their synthesis or competing with them in DNA or RNA synthesis.</li>
</ul></li>
</ul>
→max cytotoxic effects on S-phase
</p>

<h1>III.A.Methotrexate</h1>

<p>
→folic acid playes a central role in <br>
<ul style='padding-left: 30pt'>
<li>metabolic reactions
<ul>
<li>tranfer of one-carbon units</li>
</ul>
</li>
<li>essential for cell replication</li>
</ul>
→ MTX structually related to folic acid<br>
<ul style='padding-left: 30pt'>
<li>acts as an antagonist
<ul>
<li>by inhibiting dihydrofolate reductase[DHFR]</li>
</ul>
</li>
<li>converts folic acid to its active ,coenzyme form → [tetrahydrofolic acid][FH4]</li>
</ul>
</p>

<p>
1.MECHANISM OF ACTION<br>
→ obtained from dietary source   or produced by intestinal flora.
</p>

<p>
→ undergoes reduction to FH4<br>
<ul style='padding-left: 30pt'>
<li>via a reaction catalyzed by DHFR</li>
</ul>
→ MTX enter the cells<br>
<ul style='padding-left: 30pt'>
<li>by active transport process </li>
</ul>
→ at high-concentration <br>
<ul style='padding-left: 30pt'>
<li>drug diffuse into the cell </li>
<li>strong affinity for DHFR</li>
<li>effectively inhibit enzyme</li>
</ul>
→ MTX becomes polyglutamated within the cells<br>
<ul style='padding-left: 30pt'>
<li>process that favour intracellular retention of the compound
<ul>
<li>due to ↑ negative charge</li>
</ul></li>
</ul>
→ MTX-polyglutamates<br>
<ul style='padding-left: 30pt'>
<li>aslo potentialy inhibit DHFR</li>
</ul>
→ deprives the cells of folate coenzymes<br>
<ul style='padding-left: 30pt'>
<li>↓ production of compounds that depend on these coenzymes for their biosynthesis</li>
</ul>
→ nucleotides adenine,guanine,thymidine,amino acids,methionine,serines<br>
<ul style='padding-left: 30pt'>
<li>depletation of thymidine is the most promient effect</li>
</ul>
→ which leads to <br>
<ul style='padding-left: 30pt'>
<li>depressed DNA/RNA and protein synthesis  → cell death</li>
</ul>
→ only can be reserved by a thousandfold excess of the natural substrate <i>leucovorin</i><br>
<ul style='padding-left: 30pt'>
<li>which bypasses the blocked enzyme and replenishes the folate pool.</li>
</ul>
2.RESISTANCE<br>
→ non-profilating cells are resistant to MTX<br>
<ul style='padding-left: 30pt'>
<li>relative lack of DHFR</li>
<li>thymidylate synthase </li>
<li>gutamylating enzyme</li>
</ul>
→ ↓ levels of the MTX-polyglutamate in resistant cells<br>
<ul style='padding-left: 30pt'>
<li>↓ formation or ↑ breakdown</li>
</ul>
→ resistance in neoplasti cells<br>
<ul style='padding-left: 30pt'>
<li>due to amplification (production of additional copies) of the gene that codes for DHFR
<ul>
<li>resulting in ↑ levels of this enzyme</li>
</ul></li>
</ul>
→ enzyme affinity for MTX may also be diminished.<br>
3.THERAPEUTIC USE<br>
→ MTX usually in combination with other drugs	<br>
→ effective against<br>
<ul style='padding-left: 30pt'>
<li>acute lymphotic leukemia</li>
<li>choriocarcinoma</li>
<li>Burkitt lymphoma</li>
<li>breast cancer</li>
<li>head and neck carcinomas</li>
</ul>
→ low-dose MTX is effective as a single agent against certain inflammaatory diseases<br>
<ul style='padding-left: 30pt'>
<li>severe psoriasis , rheumatoid arthritis , Crohn disease</li>
</ul>
</p>

<h1>III.4.a-Pharmacokinetics</h1>

<p>
→ absorbed at low doses from GIT<br>
→ also admin. intramascular , intravenous and intrathecal routes<br>
→ does not penatrate the blood-brain-barrier<br>
→ high concentrations found in<br>
<ul style='padding-left: 30pt'>
<li>intestinal epithelium , live , kideny </li>
<li>ascites and pleural effusions.</li>
</ul>
→ MTX is also distributed to the skin.
</p>

<h1>III.4.b-Fate</h1>

<p>
→ polyglutamates which also inhibit DHFR<br>
<ul style='padding-left: 30pt'>
<li>remain within the cell even in the absence of extracellular drug.</li>
</ul>
→ high doses of MTX undergo hydroxylation at the 7 position → [7-hydroxymethotrexate]<br>
→ much less active as an antimetabolite.<br>
<ul style='padding-left: 30pt'>
<li>less water-soluble</li>
<li>lead to crystalluria</li>
</ul>
→ important to keep <br>
<ul style='padding-left: 30pt'>
<li>urine alkaline</li>
<li>patient hydrated</li>
</ul>
→ excrection of the parent drug and metabolite<br>
<ul style='padding-left: 30pt'>
<li>primarly via urine</li>
<li>feces[due to enteropathic excrection]</li>
</ul>
</p>

<h1>III.5.a.-Adverse effects</h1>

<p>
→ nausea	, vomiting , diarrhea most frequent<br>
→ stomatitis , myelosuppression , erythema , rash , urticaria , alopecia<br>
→ long term lead to cirrhosis<br>
→ MTX is teratogenic in experimental animals<br>
<ul style='padding-left: 30pt'>
<li>abortifacient </li>
<li>SHOULD BE AVOIDED in pregnancy.</li>
</ul>
</p>

<h1>III.B.-6-MERCAPTOPURINE</h1>

<p>
→ thiol analog of hypoxanthine<br>
<ul style='padding-left: 30pt'>
<li>first purine analgs</li>
</ul>
<ul>
<li><i>Azathioprine</i>
<ul>
<li>immunosuppressant,exerts its cytotoxic effects after conversion to 6-MP.</li>
<li>maintence of remission in acute lymphoblastic leukemia.</li>
<li>Crhn disease</li>
</ul></li>
</ul>
 1.MECHANISM OF ACITON<br>
<ol type="A" start="1">
<li>nucleotide formation
<ul>
<li>must penetrate target cells → along [6-MP-ribose phosphate][TIM]</li>
</ul></li>
</ol>
B.inhibition of purine synthesis<br>
<ul style='padding-left: 30pt'>
<li>metabolic processes involving purine synthesis and intercorvention are affected by the nucleotide analog
<ul>
<li>(GMP)-guanosine-monophosphate</li>
<li>(IMP)-inosine-monophosphate</li>
</ul></li>
</ul>
C.incoporation into nucleic cid<br>
<ul style='padding-left: 30pt'>
<li>TIMP converted to thio-guanine monophsosphate
<ul>
<li>which incoroporated into RNA.</li>
</ul>
</li>
<li>results in nonfunctional RNA  and DNA.</li>
</ul>
</p>

<h1>III.B.2.-Resistance</h1>

<p>
1) inability to biotransofrm 6-MP to the corresponding nucleotide because of decreased levels <br>
2)↑ dephosphorylation <br>
3)↑ metabolism of the drug to thiouric acid or other meteabolites
</p>

<h1>III.B.3.-Pharmacokinetics</h1>

<p>
→ oral roulte is erratic and incomplete<br>
→ widely distributed throughout the body<br>
<ul style='padding-left: 30pt'>
<li>except for CFS</li>
</ul>
→ bioavailability of 6-MP can be ↓ by the first pass metabolism in the liver<br>
→ <i>Alluprinol</i><br>
<ul style='padding-left: 30pt'>
<li>frequently used to reduce hyperuricemia in cancer patients
<ul>
<li>is important to ↓ the dose of 6-MP by 75%
<ul>
<li>to avoid accumulation of the drug and exacerbation of toxicities</li>
</ul></li>
</ul>
</li>
<li>parent drug excreted by the kidney.</li>
</ul>
</p>

<h1>iII.B.4.-Adverse Effects</h1>

<p>
→ bone marrow depression is the pricnipal toxicity.<br>
→ anorexia , nausea ,  vomiting , diarrhea.
</p>

<h1>III.C.6.-6-Thioguanine</h1>

<p>
→ purine analogs<br>
→ primarly used in the treatment of acute nonlymphocytic leukemia.<br>
<ul style='padding-left: 30pt'>
<li>in combinaiton with <i> daunorubicin and cytarabine</i></li>
</ul>
<ul>
<li>converted intracellulary to TGMP (6-thiogualinic acid)
<ul>
<li>further converted to di and triphosphates , thioguanosine diphosphate
<ul>
<li>which inhibit the biosynthesis of purines  and phosphprylation of GMP → guanosine diphosphate</li>
</ul></li>
</ul>
</li>
<li>nucleodite form of 6-TG incorporated into DNA that leads to cell-cycle arrest.</li>
</ul>
</p>
<h1>III.C.1.-Pharmacokinetisc</h1>

<p>
→ absorption of oral 6-TG is <br>
<ul style='padding-left: 30pt'>
<li>incomplete and erratic</li>
</ul>
→ peak conc. in the plasma is reached into 2 to 4hours.<br>
→ urin
</p>

<p>
to be continiouned,.
</p>


	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./Pharmacology/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>117kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image001.png'>pasted_image001.png</a></td><td>&nbsp;</td><td>95.1kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image002.png'>pasted_image002.png</a></td><td>&nbsp;</td><td>97.0kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
